دورية أكاديمية
Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression
| العنوان: | Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression |
|---|---|
| المؤلفون: | Frederick Berro Rivera, Sung Whoy Cha, Michelle Capahi Varona, Elaiza Marie Fernandez Co, John Vincent Magalong, John Paul Aparece, Diana De Oliveira-Gomes, Gurleen Kaur, Martha Gulati |
| المصدر: | American Journal of Preventive Cardiology, Vol 18, Iss , Pp 100645- (2024) |
| بيانات النشر: | Elsevier, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Diseases of the circulatory (Cardiovascular) system LCC:Public aspects of medicine |
| مصطلحات موضوعية: | Plaque regression, Percent atheroma volume, Plaque volume, Total atheroma volume, Fibrous cap thickness, Lipid arc, Diseases of the circulatory (Cardiovascular) system, RC666-701, Public aspects of medicine, RA1-1270 |
| الوصف: | Background: Studies reporting collective and comprehensive data on plaque regression of different lipid-lowering therapies (LLTs) are limited. Objectives: We evaluated plaque regression of LLTs based on multiple markers and performed subgroup analyses based on LLT type and post-treatment LDL-C levels Methods: A literature search was performed to identify studies assessing plaque regression from LLTs. The following LLTs groups were included: High-intensity statin (HIS), HIS+ eicosapentaenoic acid (EPA), HIS + ezetimibe, Low-intensity statin (LIS), LIS + EPA, LIS + Ezetimibe, and PCSK9 inhibitors. Our primary outcomes were change in percent atheroma volume (PAV). Secondary outcomes included mean differences in total atheroma volume (TAV), lumen, plaque, and vessel volumes, fibrous cap thickness (FCT), and lipid arc (LA). Subgroup analyses were performed on LLT type and post-treatment LDL-C levels. Meta-regression was performed to control for covariates. Results: We identified 51 studies with 9,113 adults (22 % females). LLTs reduced PAV levels (-1.10 % [-1.63, -0.56], p < 0.01), with significant reduction observed with HIS, LIS + ezetimibe, LIS + EPA, and PCSK9 inhibitors. LLTs reduced TAV levels (-5.84 mm3 [-8.64 to -3.04] p < 0.01), mainly driven by HIS (-7.60 mm3 [-11.89, -3.31] p < 0.01). LLTs reduced plaque volume and LA and increased FCT. Conclusion: The plaque regression associated with LLTs is observed to be mainly driven by HIS, reducing both TAV and PAV. This suggest that HIS is the most effective LLT for plaque regression Unstructured abstract: We evaluated plaque regression of LLTs from 51 studies. We found that while reduction of PAV (-1.10 % [-1.63, -0.56], p < 0.01) were present across different LLT types, reduction of TAV (-5.84 mm3 [-8.64 to -3.04] p < 0.01) was mainly driven by HIS (-7.60 mm3 [-11.89, -3.31] p < 0.01). These results suggest that HIS is the most effective LLT for plaque regression. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2666-6677 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2666667724000138; https://doaj.org/toc/2666-6677 |
| DOI: | 10.1016/j.ajpc.2024.100645 |
| URL الوصول: | https://doaj.org/article/81edda20713b427c9ed8bcc65c1859cc |
| رقم الأكسشن: | edsdoj.81edda20713b427c9ed8bcc65c1859cc |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 26666677 |
|---|---|
| DOI: | 10.1016/j.ajpc.2024.100645 |